Macquarie Group’s Kezar Life Sciences KZR Stock Holding History

Macquarie Group’s Portfolio KZR Stock Details KZR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-363	Closed	-$2.18K	–	1805
2024 Q2	$2.18K	Buy	+363	New	+$2.76K	﹤0.01%	1796

Other funds holding KZR

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Macquarie Group's KZR Position: Q3 2024 in Review

Macquarie Group sold out of Kezar Life Sciences (KZR) in Q3 2024, closing a stake of 363 shares — an estimated $2.18K sold.

Macquarie Group first reported a position in KZR in Q2 2024 and held it in 1 quarter. The position peaked at $2.18K in Q2 2024. 59 funds tracked by Wall St. Rank hold KZR as of Q3 2024.

Macquarie Group reported no remaining Kezar Life Sciences position as of Q3 2024 after selling out during the quarter.
Macquarie Group sold 363 Kezar Life Sciences shares in Q3 2024, an estimated $2.18K.
Macquarie Group first reported a position in Kezar Life Sciences in Q2 2024 and held it in 1 quarter.
Macquarie Group's Kezar Life Sciences position peaked at $2.18K in Q2 2024.
59 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q3 2024.

Based on Macquarie Group's 13F filing for Q3 2024, filed 14 Nov 2024.